Latest Insider Transactions at Rapid Micro Biosystems, Inc. (RPID)
This section provides a real-time view of insider transactions for Rapid Micro Biosystems, Inc. (RPID). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RAPID MICRO BIOSYSTEMS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RAPID MICRO BIOSYSTEMS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2022
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+4.9%
|
$30,000
$3.8 P/Share
|
|
Mar 17
2022
|
Sean M Wirtjes CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.96%
|
$10,000
$1.0 P/Share
|
|
Mar 14
2022
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+15.98%
|
$35,000
$1.0 P/Share
|
|
Mar 10
2022
|
Inese Lowenstein Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$60,000
$6.95 P/Share
|
|
Feb 11
2022
|
Richard A Keys CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|
|
Feb 11
2022
|
Robert G. Spignesi Jr. PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,750
+39.85%
|
-
|
|
Feb 11
2022
|
Jonathan Paris SVP, GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|
|
Feb 11
2022
|
Victoria Vezina CHIEF HUMAN RESOURCES OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
28,750
+50.0%
|
-
|
|
Feb 11
2022
|
Sean M Wirtjes CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+18.05%
|
-
|
|
Feb 11
2022
|
John J. Addington Wilson CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
61,250
+50.0%
|
-
|
|
Sep 09
2021
|
Richard S Kollender Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
107,816
+6.79%
|
$0
$0.05 P/Share
|
|
Jul 19
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.17%
|
$2,000,000
$20.0 P/Share
|
|
Jul 19
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
8,334,560
+31.9%
|
-
|
|
Jul 19
2021
|
David Hirsch Director |
BUY
Conversion of derivative security
|
Indirect |
3,344,038
+49.53%
|
-
|
|
Jul 19
2021
|
Gurinder Grewal > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
27,777
+8.61%
|
-
|
|
Jul 19
2021
|
Richard S Kollender Director |
BUY
Conversion of derivative security
|
Indirect |
1,315,084
+48.92%
|
-
|
|
Jul 19
2021
|
Longitude Capital Partners Ii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+50.0%
|
$3,000,000
$20.0 P/Share
|
|
Jul 19
2021
|
Longitude Capital Partners Ii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,344,038
+49.53%
|
-
|